FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No. MBM 1240	Serial No.: 09/927,110
	Applicant: ZHU et al	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: August 10, 2001	Group Art Unit: 1645

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA	5,759,536	06/02/1998	Bellgrau and Duke			
	AB	6,042,826	03/28/2000	Caligiuri, et al			
	AC	6,046,310	04/04/2000	Queen et al.			

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (YES/NO)
	AD	EP 0675200	04/10/95	EPO			
	AE	WO 95/32627	12/07/1995	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	AF	Ashany et al., "Th1 CD4+ Lymphocytes Delete Activated Macrophages Through the Fas/APO-1 Atigen Pathway" *Proc. Natl. Acad. Sci. USA.* **92: 11225-11229,** 1995
	AG	Batteux et al., " Gene Therapy of Experimental Autoimmune Thyroiditis by In Vivo Administration of Plasmid DNA Coding for Fas Ligand" *J Immunol.* **162: 603-608,** 1999
	AH	Batteux et al., " Transgenic Expression of Fas Ligand on Thyroid Follicular Cells Prevents Autoimmune Thyroiditis" *J. Immunol.* **164: 1681-1688,** 2000
	AI	Bellegrau et al., " A Role for CD95 Ligand in Preventing Graft Rejection" *Nature* **377:630-632,** 1995
	AJ	Bitter et al., " Expression and Secretion Vectors for Yeast" *Methods in Enzymol.* **153: 516 –544,** 1987

EXAMINER	DATE CONSIDERED
Y. Spector	6/12/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No. MBM 1240	Serial No.: 09/927,110
	Applicant: ZHU et al	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: August 10, 2001	Group Art Unit: 1645

	AK	Brown and Savill, " Phagocytosis Triggers Macrophage Release of Fas Ligand and Induces Apoptosis of Bystander Leukocytes" *J. Immunol.* **162:480-485,** 1999
	AL	Brunner et al., "Cell-autonomous Fas (CD95)/Fas-ligand Interaction Mediates Activation-induced Apoptosis in T-cell hybridomas" *Nature* **373: 441-444,** 1995
	AM	Depraetere and Golstein, " Fas and other Death Signaling Pathways" *Semin Immunol* .**9: 93-107,** 1997
	AN	Dhein et al., " Autocrine T-cell Suicide Mediated by APO-1/(Fas/CD95)" *Nature* **373: 438-441,** 1995
	AO	French et al., " Fas and Fas Ligand in Embryos and adult Mice: Ligand Expression in Several Immune-privileged Tissues and Coexpression in Adult Tissues Characterized by Apoptotic Cell Turnover" *J. Cell Biol.* **133(2): 335-343,** 1996
	AP	Griffith et al., " Fas Ligand-Induced Apoptosis as a Mechanism of Immune privilege" *Science* **270: 1189-1192,** 1995
	AQ	Hunt et al., " Fas Ligand is Positioned in Mouse Uterus and Placenta to prevent Trafficking of Activated Leukocytes Betweeb the Mother and the Conceptus" *J. Immunol.* **158:4122-4128,** 1997
	AR	Ju et al., " Fas(CD95)/FasL Interactions Required for Programmed Cell Death after T-cell Activation" *Nature* **373: 444-448,** 1995
	AS	Kiener et al., "Human Monocytic Cells Contain High Levels of Intracellular Fas Ligand" *J Immunol.* **159:1594-1598,** 1997
	AT	Kohji and Matsumoto, " Coexpression of Fas/FasL and Bax on Brain and Infiltrating T Cells in the Central Nervous System is Closely Associated with Apoptotic Cell Death During Autoimmune Encephalomyelitis"*J. Neuroimmunol.* **106:165-171,** 2000
	AU	Logan and Shenk, " Adenovirus Tripartite Leader Sequence Enhances Translation of mRNAs Late after Infection" *Proc. Natl. Acad. Sci USA.* **81(12): 3655-3659,** 1984

EXAMINER	DATE CONSIDERED
L. Spector	6/12/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No. MBM 1240	Serial No.: 09/927,110
	Applicant: ZHU et al	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: August 10, 2001	Group Art Unit: 1645

	AV	McCombe et al., "Apoptosis of VB8.2+ T lymphocytes in the Spinal Cord during Recovery from Experimental Autoimmune Encephalomyelitis Induced in Lewis Rats by Inoculation with Myelin Basic Protein" *J. Neuroimmunol Sci.*. **139:1-6,** 1996
	AW	Ogasawara et al., "Lethal Effect of the Anti-Fas Antibody in Mice" *Nature* **364: 806-809,** 1993
	AX	Okamoto et al., " Induction of Apoptosis in the Rheumatoid Synovium by Fas Ligand Gene Transfer" *Gene Therapy* **5:331-338,** 1998
	AY	Okuda et al., " The Effect of Apoptosis Inhibitors on Experimental Autoimmune Encephalomyelitis: Apoptosis as a Regulatory Factor" *Biochem . Biophys. Res. Comm.* **267: 826-830,** 2000
	AZ	Okuda et al., " Interthecal Administration of Neutralizing Antibody Against Fas Ligand Suppresses the Progression of Experimental Autoimmune Encephalomyelitis" *Biochem. Biophys. Res. Comm.* **275:164-168,** 2000
	BA	Sabelko-Downes, et al., " Dual Role for Fas Ligand in the Initiation of and Recovery from Experimental Allergis Encephalmyelitis" *J. Exp. Med.,* **189 (8):1195-1205,** 1999
	BB	Takeda et al., " Protection of Islet Allografts Transplanted together with Fas Ligand Expressing Testicular Allografts" *Diabetologia* **41:315 – 321,** 1998
	BC	Uckan et al., " Trophoblasts Express Fas Ligand: A Proposed Mechanism for Immune Privilege in Placenta and Maternal Invasion" *Mol. Hum. Reprod* **3(8):655-662,** 1997
	BD	Watanabe et al., " Expression of Fas in B Cells of the Mouse Germinal Center and Fas-Dependent Killing of Activated B Cells" *Int. Immunol.* **7:1949-1956,** 1995
	BE	Wekerle et al., "Animal Models" *Ann Neurol.* **36: S47-S53,** 1994
	BF	White et al., " B Cell Apoptosis in the Central Nervous Systems in Experimental Autoimmune Encephalomyelitis: Roles of B cell CD95, CD 95L and Bcl-2 Expression" *J Autoimmune* **14: 195-204,** 2000

EXAMINER	DATE CONSIDERED
J. Spector	6/12/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No. MBM 1240	Serial No.: 09/927,110
	Applicant: ZHU et al	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: August 10, 2001	Group Art Unit: 1645

	BG	Xerri, et al., " Fas Ligand is not only Expressed in Immune Privileged Human Organs but is also Coexpressed with Fas in Various Epithelial Tissues" *J. Clin. Mol. Pathol.* **50:87-91,** 1997
	BH	Zhang et al., " Amelioration of Collagen-induced Arthritis by CD95 (Apo-1/Fas)-Ligand gene Transfer" *J Clinical Invest.* **100: 1951-1957,** 1997

EXAMINER	DATE CONSIDERED
L. Spector	6/12/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449